NPPA orders strict enforcement of lower prices on 137 anti-cancer drugs
State drug controllers must report compliance by 16 November as the Centre moves to ensure affordable cancer care across the country.
India's drug pricing regulator has ordered state authorities to enforce immediate price cuts across 137 critical anti-cancer medications, warning hospitals, retailers, and manufacturers of strict legal action if they fail to pass the cost savings to patients.
The National Pharmaceutical Pricing Authority (NPPA), which operates under the Department of Pharmaceuticals in the Ministry of Chemicals and Fertilizers, instructed State Drug Controllers to inspect local supply chains and submit action taken reports by 16 November 2026.
Capping margins to protect patients
The policy action follows a government gazette order issued on 17 October 2026, which capped the trade margin on non-scheduled cancer medicines at 30 per cent under a trade margin rationalisation framework. The revised maximum retail prices took effect nationwide on 9 November 2026.
In total, the price caps cover 1,391 specific brands and dosage forms spanning both patented and generic anti-cancer drugs. The list of regulated treatments was compiled following recommendations from an expert committee under the Directorate General of Health Services.
| Measure | Details |
|---|---|
| Target medications | 137 non-scheduled anti-cancer drugs |
| Formulations and brands covered | 1,391 |
| Maximum allowable trade margin | 30 per cent |
| Gazette notification date | 17 October 2026 |
| Price cut effective date | 9 November 2026 |
| State compliance report deadline | 16 November 2026 |
Mandatory public price displays
Under directives issued by the NPPA, all pharmaceutical manufacturers, stockists, dealers, retailers, hospitals, and healthcare institutions must comply with the lower rates immediately. Establishments are required to display updated price lists prominently on their premises and official websites.
Revised price schedules incorporating company filings received up to 11 November 2026 have been published on the NPPA portal and made accessible through the government's Pharma Sahi Daam mobile app.
Zero tolerance for overcharging
The regulator emphasised that any failure to adhere to the capped rates will trigger overcharging proceedings under the provisions of the Drugs (Prices Control) Order, 2013.
To safeguard consumers, the NPPA has established multiple reporting channels for patients and their families. Members of the public can report instances of overcharging, artificial shortages, or non-availability of medicines through the Pharma Sahi Daam portal, the toll-free helpline (1800-111-255), or by emailing monitoring-nppa@gov.in directly.
Key numbers
| What | Figure | Source |
|---|---|---|
| Number of anti-cancer drugs capped | 137 | NPPA gazette order |
| Brands and dosage forms affected | 1,391 | NPPA office memorandum |
| Trade margin cap | 30% | Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers |
| Compliance report deadline for states | 16 November 2026 | NPPA directive to State Drug Controllers |
In this story
| Name | Role in the story |
|---|---|
| National Pharmaceutical Pricing Authority | Issued the enforcement directive and margin caps for anti-cancer drugs. |

